New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Intrinsic Therapeutics Completes $52m Financing to Fuel Commercial Efforts in the United States to Benefit Lumbar Discectomy Patients
-
FDA Expands Real-World Evidence Partnership with Brigham and Women's Hospital and Aetion
-
U.S. Venture Capital Industry Starts Strong in 2019 Following Record-Breaking Year
-
Ascension Ventures Completes Investment in Strive Health
-
CIT to Promote Virginia’s Connected Entrepreneurial Ecosystem at Annual Tom Tom Summit & Festival
-
Attest Raises $16 Million to Take the Guesswork Out of Growth for Consumer Businesses
-
Cloud Security Leader Bitglass Secures $70 Million in Growth Capital
-
Bonneville International Selects ViewLift to Power KSL's New OTT Content Platform
-
ViewLift Live and On-Demand Streaming Service Selected by Nexstar Media Group's KRON4 to Power New KRONon Digital App
-
Coursera Announces Accelerated Degree Momentum at 2019 Partners Conference
-
Desktop Metal Accelerates Shipments of the Studio System, the World’s First Office-Friendly Metal 3D Printing System
-
StreamSets Rides DataOps Momentum as Subscription Revenues Triple
-
BillionToOne Announces $15 Million Series A, Co-Led by Hummingbird and NeoTribe
-
Polyneuron Raises CHF22.5 Million in Series A to Advance Novel Therapies for Autoimmune Diseases
-
From Universal Pictures Home Entertainment: The Upside
-
Topia Appoints Veteran IT Security Expert Randy Barr to New CISO Position
-
Movius Announces $45M in Series D Financing Led by JPMorgan Chase & Co.
-
Cydan Expands Team to Accelerate Development of Innovative Treatments for Patients Living with Rare Diseases
-
CIT’s Virginia Founders Fund Invests in Ario Technologies to Enhance Workforce Training and Increase Safety in Industrial Environments
-
StreamSets to Present at Gartner Data & Analytics Summit 2019 in Orlando
-
Imara Closes a $63MM Series B Cross-Over Financing
-
OmniSci to Present Real-time Analysis Of Massive Vehicle Telematics Datasets at Gartner Data & Analytics Summit 2019
-
OmniSci Announces Speaking Appearances at NVIDIA GTC 2019
-
Get Ugly With STXfilms' 'UglyDolls Factory' Custom Character Creator
-
Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
-
DataOps Summit 2019 to Debut in San Francisco
-
Fugue Adds PCI Monitoring and Reporting to its Autonomous Cloud Compliance Solution
-
Form SC 13D/A Mersana Therapeutics, Filed by: New Enterprise Associates 14, L.P.
-
Databricks Unified Analytics Platform Takes the Stage at Gartner Data & Analytics Summit 2019
-
Form SC 13D Clementia Pharmaceutical Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A Nightstar Therapeutics Filed by: New Enterprise Associates 15, L.P.
-
Innovation expert Vijay Govindarajan and former GE CEO Jeffrey Immelt make the case that digital transformation is key to manufacturers' survival, in a significant new paper by MIT Sloan Management Re
-
Tiburio Therapeutics Inc. Appoints Nerissa Kreher, MD, Chief Medical Officer
-
Cloudflare Raises $150M and Adds to Board of Directors
-
Clementia Pharmaceuticals Inc. Obtains Interim Order for Proposed Transaction With Ipsen S.A. and Enters Into Support and Voting Agreements With Two Additional Significant Shareholders
-
Okta Enhances Customer Experience with Database Performance Monitoring
-
Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders
-
Spark + AI Summit 2019 Brings Together Global Data and Machine Learning Innovators
-
Fugue Joins Cloud Security Alliance
-
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
-
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
-
CIT GAP Funds Invests in Tympanogen to Advance Modern-Day Medical Treatments for Ear, Nose and Throat
-
Veriflow Delivers CloudPredict™ SaaS, Industry’s First Network Visibility and Assurance Platform for Multi-Cloud Environments
-
Veriflow-Sponsored Survey Finds 97 Percent of Companies Have Problems with Deploying and Managing Public Clouds
-
Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy
-
CIT GAP Funds Named Virginia’s Most Active Investor by CB Insights
-
Advancing Women in Product Launches ‘Masters of Product’ Podcast
-
Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease
-
Fugue CEO Phillip Merrick to Speak at KeyBanc Capital Markets 2019 Emerging Technology Summit
-
Form SC 13D/A GENOCEA BIOSCIENCES, Filed by: New Enterprise Associates 16, L.P.

